Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Reuss, D E; Sahm, F; Schrimpf, D; Wiestler, B; Capper, D; Koelsche, C; Schweizer, L; Korshunov, A; Jones, D T W; Hovestadt, V; Mittelbronn, M; Schittenhelm, J; Herold-Mende, C; Unterberg, A; Platten, M; Weller, M; Wick, W; Pfister, S M; von Deimling, A (2015). ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathologica, 129(1):133-146.

Wiestler, B; Capper, D; Hovestadt, V; Sill, M; Jones, D T W; Hartmann, C; Felsberg, J; Platten, M; Feiden, W; Keyvani, K; Pfister, S M; Wiestler, O D; Meyermann, R; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M; Wick, W (2014). Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 16(12):1630-1638.

Wiestler, B; Capper, D; Sill, M; Jones, D T W; Hovestadt, V; Sturm, D; Koelsche, C; Bertoni, A; Schweizer, L; Korshunov, A; Weiß, E K; Schliesser, M G; Radbruch, A; Herold-Mende, C; Roth, P; Unterberg, A; Hartmann, C; Pietsch, T; Reifenberger, G; Lichter, P; Radlwimmer, B; Platten, M; Pfister, S M; von Deimling, A; Weller, M; Wick, W (2014). Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 128(4):561-571.

Wiestler, B; Capper, D; Holland-Letz, T; Korshunov, A; von Deimling, A; Pfister, S M; Platten, M; Weller, M; Wick, W (2013). ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica:Epubahead of print.

Seystahl, K; Wiestler, B; Hundsberger, T; Happold, C; Wick, W; Weller, M; Wick, A (2013). Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. European Neurology, 69(2):95-101.

Koelsche, C; Sahm, F; Capper, D; Reuss, D; Sturm, D; Jones, D T W; Kool, M; Northcott, P A; Wiestler, B; Böhmer, K; Meyer, J; Mawrin, C; Hartmann, C; Mittelbronn, M; Platten, M; Brokinkel, B; Seiz, M; Herold-Mende, C; Unterberg, A; Schittenhelm, J; Weller, M; Pfister, S; Wick, W; Korshunov, A; von Deimling, A (2013). Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 126(6):907-915.

Wiestler, B; Claus, R; Hartlieb, S A; Schliesser, M G; Weiss, E K; Hielscher, T; Platten, M; Dittmann, L M; Meisner, C; Felsberg, J; Happold, C; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Grimm, C; Weichenhan, D; Tews, B; Reifenberger, G; Capper, D; Müller, W; Plass, C; Weller, M; Wick, W (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 15(8):1017-1026.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

This list was generated on Fri Nov 24 23:45:54 2017 CET.